ライフサイエンスコーパス: oncolytic virus

1 on-competent viruses that kill cancer cells (oncolytic viruses).

2 ise both as an immunization vector and as an oncolytic virus.

3 human cancer cells gives it potential as an oncolytic virus.

4 e promise both as a vaccine vector and as an oncolytic virus.

5 ll positioned for clinical development as an oncolytic virus.

6 h for new generations of efficiency-enhanced oncolytic viruses.

7 er exogenous genes and replication-competent oncolytic viruses.

8 popular platform for the development of such oncolytic viruses.

9 e exploited by this virus, and perhaps other oncolytic viruses.

10 ntitumor therapies, including treatment with oncolytic viruses.

11 ul tool for developing novel tumor-selective oncolytic viruses.

12 m cancer patients that were best infected by oncolytic viruses.

13 viruses or as therapeutic combinations with oncolytic viruses.

14 to consider in the preclinical evaluation of oncolytic viruses.

15 have hindered the development of therapeutic oncolytic viruses.

16 g new cell therapy strategies by arming with oncolytic viruses.

17 heterologous combination with other targeted oncolytic viruses.

18 he rationale behind combination therapy with oncolytic viruses.

19 m other viruses show promise as vaccines and oncolytic viruses.

20 ividual cancers vary in their sensitivity to oncolytic viruses.

21 great deal of progress in the development of oncolytic viruses.

22 ssive mechanisms induced by MSCs loaded with oncolytic viruses.

23 to many therapies, including the efficacy of oncolytic viruses(2); however, the role of CAFs in this

24 se reduction of doses of a relatively potent oncolytic virus, a finding with implications for the dev

25 eratively contribute towards mediating rapid oncolytic virus activity.

26 hampered by the relatively elevated doses of oncolytic viruses administered in animal models to achie

27 ach we presented here may pave a new way for oncolytic virus administration using cells as carriers.

28 he critical question of how MSCs loaded with oncolytic viruses affect virotherapy outcomes and tumor

29 ination of a metabolite-derived drug with an oncolytic virus agent can greatly improve anticancer the

30 a cytopathic SV5 P/V mutant can serve as an oncolytic virus and that the oncolytic effectiveness of

31 is currently being considered as a clinical oncolytic virus and vaccine vector.

32 mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibiti

33 be used to study therapies involving various oncolytic viruses and chemotherapeutics, with the goal o

34 vides a new rationale for the combination of oncolytic viruses and chemotherapy.

35 to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critica

36 subject to treatment with immunostimulatory oncolytic viruses and dendritic cell vaccines.

37 be adapted for ferrying ribonucleocapsids of oncolytic viruses and gene delivery vectors.

38 Understanding the interactions between oncolytic viruses and the innate immune system will faci

39 e we test whether the inflammatory nature of oncolytic viruses and their ability to remodel the tumor

40 n comparison with other clinically evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment s

41 de, adoptive cell therapy and treatment with oncolytic viruses, and discuss emerging combination stra

42 ation that could be used in both vaccine and oncolytic virus applications.

43 Oncolytic viruses are a promising treatment for patients

44 Replicating oncolytic viruses are able to infect and lyse cancer cel

45 Oncolytic viruses are an active area of clinical researc

46 Oncolytic viruses are an innovative therapeutic strategy

47 aside from stimulating immune infiltration, oncolytic viruses are attractive means to deliver agents

48 tained in their pleomorphic forms.IMPORTANCE Oncolytic viruses are being developed for cancer therapy

49 Oncolytic viruses are being explored as a means to selec

50 Oncolytic viruses are genetically altered replication-co

51 Oncolytic viruses are genetically modified viruses that

52 Mesenchymal stem cells (MSCs) loaded with oncolytic viruses are presently being investigated as a

53 TANCE Vesicular stomatitis virus (VSV)-based oncolytic viruses are promising agents against pancreati

54 Vesicular stomatitis virus (VSV) based oncolytic viruses are promising agents against various c

55 Replication-competent herpes simplex oncolytic viruses are promising anticancer agents that p

56 Oncolytic viruses are promising therapeutics that can se

57 These studies indicate that oncolytic viruses are remarkably safe and more efficacio

58 Oncolytic viruses are used increasingly for cancer thera

59 Engineering an oncolytic virus armed with a CXCR4 antagonist represents

60 tacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the

61 we have generated immune cells infected with oncolytic viruses as a therapeutic strategy that can com

62 it is important to continue to develop novel oncolytic viruses as well as support basic research into

63 he rational design of the next generation of oncolytic viruses, as well as the discovery of efficacio

64 Oncolytic viruses based on adenovirus type 5 (Ad5) have

65 s aimed at promoting the optimum efficacy of oncolytic virus-based anticancer immunotherapies.

66 is important for understanding and improving oncolytic virus-based therapies.

67 ating older approaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

68 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of can

69 ts and ultimately undermines the efficacy of oncolytic viruses, both in vitro and in vivo.

70 atment of disease as a vaccine vector and an oncolytic virus, but infection of the brain remains a co

71 proposed as tools to increase the potency of oncolytic viruses, but there is a need for mechanisms to

72 y therefore augment the therapeutic index of oncolytic viruses by inhibiting replication in normal ce

73 Second, the challenges of delivering oncolytic viruses by the intravenous route hamper the br

74 incorporation of fusogenic function into an oncolytic virus can significantly increase the potency o

75 ansductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect

76 oregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immun

77 ng chimeric antigen receptor T cell therapy, oncolytic viruses, cancer vaccines and immune-checkpoint

78 nt tumor cell killing makes it an attractive oncolytic virus candidate that may provide clinical bene

79 Checkpoint inhibitors, oncolytic viruses, cell-based immunotherapies, cytokines

80 rapeutics paper highlights key milestones in oncolytic virus clinical development, discusses the chal

81 Replication-selective oncolytic viruses constitute a rapidly evolving and new

82 When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical

83 Oncolytic viruses could provide a safe alternative for t

84 One of the limitations observed with oncolytic viruses currently used in the treatment of sol

85 vector (Ad5) and constructed an HCC-specific oncolytic virus, CV890.

86 lation of transgene circuitry in VV-vectored oncolytic virus design.

87 Oncolytic viruses designed to attack malignant cells can

88 pproach is the use of replication-competent "oncolytic viruses" designed to specifically target and d

89 oxvirus family that is being developed as an oncolytic virus, DHX9, forms unique granular cytoplasmic

90 the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD

91 Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in ped

92 an alternative region of dosing space (lower oncolytic virus dose, higher dendritic cell dose) for wh

93 However, when oncolytic virus doses were reduced (3 x 10(3) and 3 x 10

94 infiltration of the tumor with immune cells, oncolytic viruses, drugs, and other therapeutics.

95 -FH has significant advantages over MV as an oncolytic virus due to its higher viral yield, faster re

96 s a first step towards understanding spatial oncolytic virus dynamics, upon which more detailed inves

97 Both HP-NAP protein and oncolytic viruses encoding HP-NAP have been suggested as

98 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

99 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

100 t that intratumoral immunomodulation with an oncolytic virus expressing a rationally selected ligand

101 Oncolytic viruses expressing inert soluble marker polype

102 ccines against infectious diseases and as an oncolytic virus for cancer therapy.

103 icular stomatitis virus (VSV) is a potential oncolytic virus for treating glioblastoma multiforme (GB

104 V) is currently being studied as a candidate oncolytic virus for tumor therapies due to its potent tu

105 accelerate the engineering of the genomes of oncolytic viruses for the insertion of immunomodulatory

106 ow the efficacy of systemically administered oncolytic viruses for the treatment of spontaneously ari

107 Optimization of oncolytic viruses for therapeutic applications requires

108 stomatitis virus have recently been used as oncolytic viruses for tumor therapies and are being deve

109 Since then, oncolytic viruses from five different species have been

110 his drug with a herpes simplex virus-2-based oncolytic virus (FusOn-H2) against Lewis lung carcinoma,

111 um iodide symporter (NIS) (VSV-mIFNbeta-NIS) oncolytic virus has significant antileukemia activity, w

112 Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatm

113 Interest in the potential of oncolytic viruses has grown steadily over the past two d

114 To date, four OVs and one non-oncolytic virus have been approved for the treatment of

115 Oncolytic viruses have been tested against many carcinom

116 Replication-selective oncolytic viruses have emerged as a new treatment platfo

117 The antitumoral effects of oncolytic viruses have generally been limited by ineffic

118 eplication and propagation in tumor tissues, oncolytic viruses have had only limited antitumor effect

119 Clinical and/or preclinical studies on oncolytic viruses have revealed that the candidate virus

120 Oncolytic viruses hold promise for the treatment of canc

121 Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-negative

122 ORF in the locus deleted in the FDA-approved oncolytic virus Imlygic.

123 way to enhance the antitumor effects of this oncolytic virus in future clinical trials.

124 analyzed by PCR reveals the presence of the oncolytic virus in the brains, livers, spleens, kidneys,

125 in the potential treatment of gliomas, with oncolytic viruses in particular showing significant prom

126 intravenous route hamper the broader use of oncolytic viruses in the clinic.

127 ed human clinical investigations for several oncolytic viruses in the treatment of gliomas.

128 Selective replication of oncolytic viruses in tumor cells provides a promising ap

129 them an advantage over interferon-sensitive oncolytic viruses in tumors showing residual interferon

130 ith regard to replication of the recombinant oncolytic viruses in tumour cells.

131 ancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo.

132 icacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytot

133 Oncolytic viruses, including oncolytic herpes simplex vi

134 Recently, however, many oncolytic viruses, including reovirus, have been reporte

135 rain (Rt3D)-palbociclib combination augments oncolytic virus-induced stress responses and increases i

136 ptive transfer of normal T cells loaded with oncolytic virus into individuals with cancer would be te

137 In summary, this engineered oncolytic virus is able to activate tumor neoantigen-spe

138 We find that the oncolytic virus is able to secrete the PD-L1 inhibitor t

139 An HSV-1-derived oncolytic virus is currently approved by the US FDA and

140 ired immunity, as the antitumor effect of an oncolytic virus is mainly generated during the acute pha

141 VSV as an oncolytic virus is particularly appealing for its except

142 the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and pr

143 epigenome-targeting drugs with oncogenic and oncolytic viruses is a highly significant area of invest

144 show that MSC-mediated systemic delivery of oncolytic viruses is a promising strategy for achieving

145 The cancer-selective nature of some oncolytic viruses is based on the impaired innate immuni

146 ting of tumor cells by replication-competent oncolytic viruses is considered indispensable for realiz

147 l environment and the genetic composition of oncolytic viruses is crucial for the development of effi

148 fects either on the cancer patient or on the oncolytic virus itself if they are expressed at the wron

149 VEGF165 inhibitors with systemic delivery of oncolytic viruses leads to substantial regression and cu

150 The increased therapeutic potency of this oncolytic virus may be useful in the treatment of a wide

151 As such, selective replication-competent oncolytic viruses may be useful as a potential treatment

152 nate immune effector mechanisms triggered by oncolytic viruses may contribute to the clearance of bot

153 Yet off-target infections by oncolytic viruses may increase virus production, further

154 ence demonstrating the concept of a combined oncolytic virus-mediated tumor diagnosis and therapy sys

155 This new oncolytic virus (MGH2) displays increased antitumor effi

156 Therefore, effective replication of HSV oncolytic viruses might be limited to a subpopulation of

157 In particular, an oncolytic virus must be resistant to the inhibition of D

158 ancer stemlike cells, cell cycle regulation, oncolytic viruses, new radiotherapy techniques, and immu

159 This study examined the behavior of two oncolytic viruses, NV1020 and G207, during liver regener

160 Oncolytic viruses obliterate tumor cells in tissue cultu

161 Oncolytic viruses offer a promising approach, with the u

162 Oncolytic viruses offer an approach to destroy tumors by

163 Oncolytic viruses offer an in situ vaccination approach

164 Oncolytic viruses offer potential treatment but need imp

165 Oncolytic viruses offer the attractive therapeutic combi

166 VSV is one oncolytic virus out of an arsenal of potential candidate

167 icular stomatitis virus (VSV) is a promising oncolytic virus (OV) against different malignancies, inc

168 Drug Administration approval of immunogenic oncolytic virus (OV) has opened a new era in the treatme

169 Oncolytic virus (OV) immunotherapies selectively kill GB

170 herapeutic outcomes may be achieved by using oncolytic virus (OV) in combination with a potent immune

171 Farrar et al demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein

172 Oncolytic virus (OV) therapies of cancer are based on th

173 Oncolytic virus (OV) therapy has emerged as a novel tool

174 IMPORTANCE Oncolytic virus (OV) therapy is a promising virus-based

175 Oncolytic virus (OV) therapy is a promising virus-based

176 ng VSV attachment and replication.IMPORTANCE Oncolytic virus (OV) therapy is an anticancer approach t

177 es of a hypoxia-regulated, prostate-specific oncolytic virus (OV) to prostate tumors.

178 ized that co-treatment with the inflammatory oncolytic virus (OV) vesicular stomatitis virus (VSV-IFN

179 and cancer cells leads to enhanced growth of oncolytic virus (OV)-based therapeutics.

180 mmunodominant T cell response into tumors by oncolytic virus (OV)-mediated or chimeric antigen recept

181 icular stomatitis virus (VSV) is a promising oncolytic virus (OV).

182 Oncolytic viruses (OV) and ultrasound-enhanced drug deli

183 Since oncolytic viruses (OV) can generate a highly immune-infi

184 As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see

185 We have shown that oncolytic viruses (OV) injected into intracranial glioma

186 Oncolytic viruses (OV) preferentially kill cancer cells

187 Oncolytic viruses (OV) such as reovirus preferentially i

188 rtantly, the intratumoral injection with the oncolytic virus overcomes PD-L1-mediated immunosuppressi

189 Oncolytic viruses (OVs) are an emerging class of cancer

190 Oncolytic viruses (OVs) are being optimized to treat can

191 wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potentia

192 Oncolytic viruses (OVs) are emerging as important agents

193 Oncolytic viruses (OVs) are promising therapeutics that

194 Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer.

195 The therapeutic effectiveness of oncolytic viruses (OVs) delivered intravenously is limit

196 Oncolytic viruses (OVs) emerge as a promising cancer imm

197 Oncolytic viruses (OVs) encoding a variety of transgenes

198 ng immunoshielding agents that could protect oncolytic viruses (OVs) from neutralizing antibodies (nA

199 In the last two decades, different oncolytic viruses (OVs) have been modified and tested in

200 himeric antigen receptor T (CAR-T) cells and oncolytic viruses (OVs) have emerged as promising cancer

201 Oncolytic viruses (OVs) hold promise for cancer treatmen

202 The mode of action for oncolytic viruses (OVs) in cancer treatment is thought t

203 Oncolytic viruses (OVs) provide novel and promising ther

204 Oncolytic viruses (OVs) represent a new class of multi-m

205 Oncolytic viruses (OVs) represent a novel class of cance

206 Genetically engineered oncolytic viruses (OVs) with immunomodulators are promis

207 apies that engage the immune system, such as oncolytic viruses (OVs), hold great promise and are desp

208 s an overview of the mechanisms of action by oncolytic viruses (OVs), including direct oncolysis, imm

209 Oncolytic viruses (OVs), viruses engineered to lyse tumo

210 , but antibody neutralization of circulating oncolytic virus particles remains a formidable barrier.

211 ptosis and highlights the critical role that oncolytic viruses play in the treatment of drug-resistan

212 Oncolytic viruses pose many questions in their use in ca

213 on with other immunotherapies, suggests that oncolytic viruses possess significant therapeutic potent

214 illing, promotion of local immune responses, oncolytic virus production, and prodrug activation schem

215 patients treated with adjuvant anti-PD-1 or oncolytic virus (PVSRIPO) showed a trend towards improve

216 Oncolytic viruses replicate selectively in tumor cells a

217 Oncolytic virus replication at a tumor site may not be a

218 ce to chemotherapy, plays a positive role in oncolytic virus replication in most of the tested human

219 ide and CPT-11 does not significantly affect oncolytic virus replication.

220 ide metabolic support to tumor immunity, and oncolytic viruses represent a platform to deliver metabo

221 As such, oncolytic viruses represent a promising cancer-specific

222 elatively potent herpes simplex virus type 1 oncolytic virus (rQNestin34.5) produces 45% survivors at

223 Oncolytic viruses selectively lyse tumor cells, disrupt

224 RI) system to direct macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic

225 Implications for the initial dynamics of oncolytic virus spread through tumors are discussed.

226 e preclinical studies, melanin overproducing oncolytic virus strains might be used in clinical trials

227 Oncolytic viruses such as vesicular stomatitis virus (VS

228 Other oncolytic viruses, such as adenovirus, vesicular stomati

229 s being developed presently as a therapeutic oncolytic virus [talimogene laherparepvec (T-VEC)].

230 the state of current research on the use of oncolytic viruses targeted to stem cells as a potential

231 Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thu

232 In this study, we generate an engineered oncolytic virus that coexpresses a PD-L1 inhibitor and G

233 rrVSV-G is a new targeted oncolytic virus that has potent antitumor capabilities a

234 utant HSV1716 is a conditionally replicating oncolytic virus that selectively replicates in and lyses

235 Currently, no oncolytic viruses that are able to kill only tumor cells

236 Oncolytic viruses that can destroy cancer cells have bee

237 of new therapeutic genes into the genome of oncolytic viruses that could not have been tested otherw

238 Similar to other oncolytic viruses, the likelihood of delivering CVA21 by

239 To create effective oncolytic virus therapies for pancreatic cancer, it is c

240 We explored the use of oncolytic virus therapy against glioblastoma with Zika v

241 this approach might increase the efficacy of oncolytic virus therapy and to identify gaps in knowledg

242 f a safe and effective live-virus vector for oncolytic virus therapy and vaccines against smallpox, o

243 These data indicate that the use of VSV for oncolytic virus therapy for prostate tumors may require

244 Oncolytic virus therapy has shown activity against prima

245 Oncolytic virus therapy is being evaluated in clinical t

246 Mathematical modeling of oncolytic virus therapy is often limited by the fact tha

247 A major challenge to oncolytic virus therapy is that individual cancers vary

248 One of the several impediments to effective oncolytic virus therapy of cancer remains a lack of tumo

249 s recombinant vaccinia vSP shows promise for oncolytic virus therapy.

250 to the burgeoning fields of cancer-killing (oncolytic) virus therapy with vaccinia virus (VACV).

251 nlike our previous findings with less potent oncolytic viruses, though, the preadministration of cycl

252 randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor.

253 human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus au

254 T cell trafficking in order to chaperone an oncolytic virus to lymphoid organs harboring metastatic

255 s, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells.

256 e injection site has limited the capacity of oncolytic viruses to achieve consistent therapeutic resp

257 cy and the ability to be combined with other oncolytic viruses to enhance treatment results or to cre

258 diation interacts with replication-competent oncolytic viruses to enhance viral replication and tumor

259 Engineering oncolytic viruses to express leptin in tumor cells induc

260 adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new

261 method to overcome this challenge is to use oncolytic viruses to induce secondary antitumor immune r

262 r than completely eliminating the ability of oncolytic viruses to infect and lyse normal cells could

263 horses' to improve the delivery of drugs and oncolytic viruses to intractable tumours and are also be

264 into the interaction between CAR T cells and oncolytic viruses to optimize combination therapy.

265 A workshop "Targeting Oncolytic Viruses to Tumor Stem Cells," organized by the

266 inistering a single dose of TGFbeta prior to oncolytic virus treatment of glioblastoma can transientl

267 nificantly enhanced both animal survival and oncolytic virus tumor distribution and also reduced tumo

268 mide did not enhance this survival or affect oncolytic virus tumor distribution and tumor volume.

269 Oncolytic viruses used for gene therapy have been geneti

270 In this study, we combined ACT with oncolytic virus vaccines (OVVs) to drive expansion and t

271 ers that can bind noncovalently to an intact oncolytic virus, vaccinia virus (VACV), which can select

272 e enhanced functional studies, generation of oncolytic virus vectors, development of delivery platfor

273 ugh intravascular administration may deliver oncolytic viruses/vectors to each of these tumors, its e

274 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and t

275 is work, we selected DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to pr

276 Replication-selective oncolytic viruses (virotherapeutics) are being developed

277 ning of the first clinical trial in which an oncolytic virus was administered to cancer patients.

278 immune responses, to enhance the activity of oncolytic viruses, we evaluated the effect of coadminist

279 Unlike many other oncolytic viruses, we found no evidence that impairment

280 dentify the effector mechanisms activated by oncolytic viruses, we investigated inhibition of prolife

281 However, responses to oncolytic viruses were incomplete due to metabolic insuf

282 The murine oncolytic viruses were successfully armed with murine gr

283 Oncolytic viruses, which replicate in cancer cells, indu

284 Conditionally replicating (oncolytic) viruses, which selectively replicate in tumor

285 e cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on

286 s designed to enhance the potency of current oncolytic viruses will likely increase their chance of c

287 Here, we report an approach to arm an oncolytic virus with CD40 ligand (CD40L) to stimulate be

288 rotein and Fcy::Fur provides a highly potent oncolytic virus with improved capabilities for local tum

289 novirus is a promising replication-selective oncolytic virus with targeting specificity for EBV-assoc

290 Our data demonstrate that combining an oncolytic virus with tumor-targeting immune checkpoint m

291 ons may allow for the generation of modified oncolytic viruses with greater selective tumor cell repl

292 mathematical framework for assessing whether oncolytic viruses with reduced tumor-specificity can mor

293 t, much effort is being focused on combining oncolytic viruses with standard treatment modalities suc

294 Using replication-competent HSV-1 oncolytic viruses with thymidine kinase (TK) under contr